Anti-seizure medications (ASMs): monitoring
Evidence-based neurology checklist on anti-seizure medications (asms): monitoring: Blood level monitoring: general indications To establish individual therapeutic concentration To assess toxicity To check compliance To guide dose adjustment To assess expected pharmacokinetic change in pregnancy To…
Blood level monitoring: general indications
- To establish individual therapeutic concentration
- To assess toxicity
- To check compliance
- To guide dose adjustment
- To assess expected pharmacokinetic change in pregnancy
- To assess expected pharmacokinetic change with addition or removal of interacting drug
- To monitor generic substitution
Blood level monitoring: indications for assessing pharmacological variability
Blood level sampling
Monitoring indices for enzyme-inducing AEDs (2-5 yearly)
Periodic monitoring for hyponatraemia
References
- Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommittee on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239-1276.
- Stepanova D, Beran RG. The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy. Epilepsy Behav 2015; 42:7-9.
- The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE Clinical Guideline [CG137]. January 2012.
- Berghuis B, van der Palen J, de Haan GJ, Lindhout D, Koeleman BPC, Sander JW; EpiPGX Consortium. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia 2017; 58:1227-1233.
- Kim YS, Kim DW, Jung KH, et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure 2014; 23:208-212.
